The U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health released a discussion paper on how to evaluate the benefits and risks of robotic medical devices with autonomous functions or remote teleoperation. The paper examines autonomous functions, in which a device performs tasks without continuous clinician control, and remote teleoperation, in which a clinician controls the device from a different location. The FDA’s September 2026 draft guidance on certain robotically assisted surgical devices excludes remotely teleoperated devices and robots that perform significant parts of a surgical procedure independently of a qualified practitioner. An earlier post on The Consult covers the proposed premarket recommendations. The discussion paper also covers a broader range of devices than surgical robots, including devices used for diagnostic, therapeutic, or rehabilitative tasks, such as remotely operated ultrasound.
The FDA will discuss the paper at a hybrid public workshop on December 2 and 3, 2026. The agency is accepting public comments through January 5, 2027, under docket FDA-2026-N-13135.
The FDA asks what clinical and nonclinical evidence could help characterize the benefits and risks of autonomous functions under typical and worst-case conditions. Autonomous functions can vary substantially in scope. A device that performs one defined step while a surgeon controls the rest of the operation may present different risks from a device that generates and executes a patient-specific surgical plan under supervision. The discussion paper therefore considers how the extent of a device’s autonomy, the clinician’s role in supervising it, and the ability to interrupt or override its actions should affect the benefit-risk assessment. The safety of an override may depend on whether the clinician can recognize a problem and intervene in time.
The FDA asks how emergency management, conversion to a manual procedure, and possible patient transfer should factor into the benefit-risk assessment. Remote teleoperation presents a different set of questions because the clinician and patient are in separate locations. The discussion paper focuses in part on the facility where the patient receives care. A hospital may be able to offer a procedure because a specialist can control the device remotely, but that same hospital may have limited ability to manage a complication or complete the procedure manually if the connection fails.
Recent Comments